Revenue: As of FY2025 Q2, the actual value is USD 2.33 M.EPS: As of FY2025 Q2, the actual value is USD -0.13.EBIT: As of FY2025 Q2, the actual value is USD -1.523 M.<h3>Segment Revenue</h3><ul><li>Benchtop Laboratory Equipment: Revenue for the three months ended June 30, 2025, was $2,106,200, a decrease from $2,281,900 in the same period in 2024. For the six months ended June 30, 2025, revenue was $4,379,200, compared to $4,449,300 in 2024.</li><li>Bioprocessing Systems: Revenue for the three months ended June 30, 2025, was $223,700, down from $365,400 in 2024. For the six months ended June 30, 2025, revenue was $357,200, compared to $681,500 in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: The net loss for the three months ended June 30, 2025, was $1,522,700, compared to $1,283,600 in 2024. For the six months ended June 30, 2025, the net loss was $3,302,200, compared to $3,335,200 in 2024.</li><li>Gross Profit: The gross profit percentage for the three months ended June 30, 2025, was 43.8%, down from 48.8% in 2024. For the six months ended June 30, 2025, it was 43.0%, compared to 45.5% in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended June 30, 2025, were $2,565,300, compared to $2,628,600 in 2024. For the six months ended June 30, 2025, operating expenses were $5,394,000, compared to $5,758,900 in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities for the six months ended June 30, 2025, was - $2,762,900, compared to - $2,436,800 in 2024.</li><li>Investing Cash Flow: Net cash provided by investing activities for the six months ended June 30, 2025, was $1,580,700, compared to $1,570,700 in 2024.</li><li>Financing Cash Flow: Net cash provided by financing activities for the six months ended June 30, 2025, was $1,452,200, compared to $645,700 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to focus on increasing sales of its Torbal brand products and addressing customer delays in the Bioprocessing Systems segment. The company is also working on new product developments in the Bioprocessing Systems Operations.</li><li>Non-Core Business: The company entered into an Asset Purchase Agreement to sell the Genie Division of its Benchtop Laboratory Equipment Operations, which is expected to provide a purchase price of $9,600,000 minus certain adjustments, plus an earn-out up to $1,500,000.</li></ul>

Scientific Industries, Inc. | 10-Q: FY2025 Q2 Revenue: USD 2.33 M